A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Ritonavir-Boosted DANOPREVIR and RO5024048 in Different Combinations in Null Responder or Treatment Naive Patients With Chronic Hepatitis C and Compensated Cirrhosis
Phase of Trial: Phase II
Latest Information Update: 03 Aug 2016
At a glance
- Drugs Mericitabine (Primary) ; Danoprevir; Peginterferon alfa-2a; Ribavirin; Ritonavir
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Roche
- 03 Aug 2016 Last checked against ClinicalTrials.gov record.
- 03 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 28 Jan 2014 New source identified and integrated.European Clinical Trial Database Record.